AstraZeneca's breast cancer drug failed to meet the main goal of improving progression-free survival during a late-stage trial, it said on Friday, marking a setback for the recently approved ...
AstraZeneca’s breast cancer pill camizestrant (Etcamah) failed to improve progression-free survival in a late-stage trial when added to standard therapy, despite an earlier ESR1 mutation–targeted ...
AstraZeneca’s Camizestrant failed the main goal in the SERENA-4 breast cancer trial The drug showed numerical but not statistically significant improvement in progression-free survival FDA recently ...
The Manila Times on MSN
AstraZeneca’s breast cancer pill falls shortASTRAZENECA’S AZN.L breast cancer pill failed to meet the main goal of improving progression-free survival in a late-stage trial, the company said on Friday, a week after the treatment received US ...
AstraZeneca said its new breast-cancer pill missed the key goal of slowing the disease from worsening in a late-stage clinical trial. The U.K. drugmaker evaluated its Etcamah medicine, in combination ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Sept 11 — AstraZeneca's breast cancer drug failed to meet the main goal of improving progression-free survival during a late-stage trial, it said on Friday, marking a setback for the recently ...
US-listed shares of AstraZeneca dropped about 3 per cent in aftermarket trading following the news. AstraZeneca said the full trial data will be shared in due course.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results